YYY
Lv11
70 积分
2022-01-19 加入
-
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2小时前
已完结
-
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2小时前
已完结
-
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
8天前
已完结
-
The Impact of Histologic Liver Inflammation on Oncology and the Prognosis of Patients Undergoing Hepatectomy for Hepatocellular Carcinoma
12天前
已完结
-
Circ_0000591 served as endogenous RNA for miR-326 to promote progression of cholangiocarcinoma via the TLR4/MyD88/IL6 axis
2个月前
已完结
-
Sequencing Systemic Therapy in Hepatocellular Carcinoma
4个月前
已完结
-
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
6个月前
已完结
-
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
8个月前
已完结
-
Can the new adipokine asprosin be a metabolic troublemaker for cardiovascular diseases? A state-of-the-art review
9个月前
已完结
-
Asprosin, a novel glucogenic adipokine implicated in type 2 diabetes mellitus
9个月前
已完结